Advertisement

Boston’s Prexa Pharmaceuticals Inc. has brought in $3.25 million of a $7 million equity round, according to a filing with the U.S. Securities and Exchange Commission.

The company, founded in 2006 according to its website, is developing small molecule monoamine reuptake inhibitors focused on enhancing dopamine activity with the goal of improving on treatments for central nervous system disorders ADHD, depression and Parkinson’s disease.

SOURCE

Advertisement
Advertisement